During the same quarter previous year, the firm earned $3.15 earnings per share.
Advertisement
Learn how you could trade stocks with 91% to 100% success rate by using this revolutionary indicator that predicts when certain stocks are on the move. The price target estimates represents a standard deviation of 11.20.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. For the reporting quarter, analysts expect the company to deliver $2.89 in earnings per share (EPS). However, revenue still beat estimates of $7.77 billion. The company’s quarterly revenue was down 5.7% on a year-over-year basis. Gilead Sciences’s revenue was down 5.7% compared to the same quarter previous year.
GILD has been the topic of several recent analyst reports. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $105.42 price objective on the stock.in a research report on Thursday, April 21st. Jefferies Group reissued a “hold” rating and issued a $97.00 price target on shares of Gilead Sciences in a report on Friday, July 15th. The investment management company now holds a total of 431,368 shares of Gilead Sciences which is valued at $37,334,900 after selling 11,610 shares in Gilead Sciences, the firm said in a disclosure report filed with the SEC on Jul 21, 2016.Gilead Sciences makes up approximately 8.30% of Gryphon International Investment Corp’s portfolio.
The Company has received rating from WSJ analysts. Gilead Sciences now has an average rating of “Buy” and a consensus price target of $109.95.
Gilead Sciences Inc. value Change from Open was at -1.23% with a Gap of -0.79%. The stock had a trading volume of 14.1 M shares. The company has market capitalization of $108.13B. The 20 day simple moving average is -5.73% and the 200 day simple moving average is -13.99%. Shareholders of record on Friday, September 16th will be paid a $0.47 dividend. The ex-dividend date is Wednesday, September 14th.
In other news, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Now the stock has been rated as “Buy” from 9 Analysts. On Jul 6, 2016, Paul Rutherford Carter (EVP Commercial Ops) sold 2,000 shares at $83.12 per share price, according to the Form-4 filing with the securities and exchange commission. The stock was sold at an average price of $87.71, for a total value of $9,823,520.00. Following the completion of the transaction, the executive vice president now owns 62,939 shares of the company’s stock, valued at $5,583,948.08. Gilead Sciences Inc.is in the Biotechnology industry and Healthcare sector.
Advertisement
07/25/2016 – Gilead Sciences, Inc. had its “strong buy” rating reiterated by analysts at S&P Capital IQ. Hendershot Investments Inc. raised its position in shares of Gilead Sciences by 2.5% in the fourth quarter. The company recorded a trading capacity of 1.1 million shares below its three months average daily volume of 1.16 million shares. Geode Capital Management LLC increased its stake in shares of Gilead Sciences by 1.3% in the first quarter. Analysts anticipate that Gilead Sciences will post $11.81 EPS for the current year.
